
MiMedx Group (MDXG) Stock Forecast & Price Target
MiMedx Group (MDXG) Analyst Ratings
Bulls say
MiMedx Group Inc has increased its 2025 revenue estimate to $387.3 million from $374.0 million, reflecting strong second-quarter results and significant growth in its surgical business. The company reported revenue of $98.6 million for the most recent quarter, achieving a year-over-year growth of approximately 13%, with notable contributions from the wound portfolio and surgical segments, which grew by 12% and 15%, respectively. Although selling, general, and administrative expenses rose roughly 16% year-over-year to $64.2 million due to higher sales commission rates and legal costs, the overall revenue trajectory indicates a positive growth outlook for MiMedx Group.
Bears say
MiMedx Group Inc's gross margin has decreased to approximately 81%, down from 83% in the previous quarter, a trend attributed to production variances and changes in product mix. Although the company maintains guidance of achieving low double-digit percentage year-over-year revenue growth and an adjusted EBITDA margin above 20%, these forecasts may be overshadowed by external risks. Furthermore, potential negative changes in reimbursement rates by CMS could significantly adversely impact the firm's financial performance, contributing to a negative outlook.
This aggregate rating is based on analysts' research of MiMedx Group and is not a guaranteed prediction by Public.com or investment advice.
MiMedx Group (MDXG) Analyst Forecast & Price Prediction
Start investing in MiMedx Group (MDXG)
Order type
Buy in
Order amount
Est. shares
0 shares